With over $2B assets under management, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies, focusing on Life Sciences and Growth Buyout investments.

Life Sciences

IPO in 2015 (NASDAQ: COLL)
Acquired by The Medicines Company in 2012
Acquired by Valeant Pharmaceuticals in 2014
Acquired by The Medicines Company in 2013

Growth Buyout



Novo Nordisk to acquire Calibrium LLC

Frazier Healthcare Partners

Tachi Yamada, M.D., Former Head of GSK and Takeda R&D, Re-Joins Frazier Healthcare as Venture Partner

DSI Renal

DSI Renal Reaches 100 Dialysis Clinics Milestone

ProNAi Therapeutics

ProNAi Therapeutics Announces Pricing of Initial Public Offering